Actively Recruiting
Phase 2 Study to Test Safety and Effectiveness of Oral Infigratinib in Children Under 3 Years with Achondroplasia
Led by QED Therapeutics, a BridgeBio company · Updated on 2026-07-13
77
Participants Needed
12
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 2, multicenter, randomized, placebo-controlled clinical trial to study infigratinib in children younger than 3 years old with achondroplasia ACH. The study aims to identify and confirm the appropriate dose of infigratinib based on safety and pharmacokinetics PK, and then evaluate its safety and effectiveness compared to placebo in this young population. The trial includes several parts to carefully assess the medication in different age cohorts and settings. The trial has four parts a single ascending dose SAD portion where doses are increased in small groups to find the right dose for each age group, an open-label Phase 2 portion to confirm these doses, a Phase 2b placebo-controlled portion to evaluate safety and efficacy in randomized groups, and an extension period for ongoing safety and efficacy assessment until children reach 3 years old plus six months. Infigratinib is given orally as minitablets or sprinkle capsules, with doses adjusted for age and weight, typically every 3 months during the first year and every 6 months afterward. Participants will be closely monitored throughout the study, with visits including safety checks, growth measurements, developmental milestones, brain and bone imaging, and quality of life assessments. The study team will track adverse events and any surgical interventions related to ACH. The total participation may last up to three and a half years depending on when the child enrolls and their age, ensuring thorough long-term safety and efficacy data collection.
CONDITIONS
Brief Title
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
Research Team
Q
QED Therapeutics Inc.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here